Skip to main content

Kymera Therapeutics, Inc.

corporate_fare Company Profile

Kymera Therapeutics, Inc.

KYMR·NASDAQ·Life Sciences·CIK 0001815442

We are a clinical-stage biopharmaceutical company focused on developing innovative oral medicines to treat human diseases. We aim to advance novel technologies to target disease-causing biology that has not been adequately addressed by existing treatments. Our approach is designed to discover and develop new medicines in a disease-agnostic manner. We are a leader in targeted protein degradation (TPD), a small molecule therapeutic method that uses the body's natural cellular recycling system to eliminate disease-causing proteins. Our goal is to develop potent and highly selective molecules to address diseases poorly served by current treatments. We have advanced multiple programs into clinical development and expect to advance at least one new molecular entity into clinical testing annually. We intend to become a fully integrated biopharmaceutical company with a pipeline of novel medicines. Our current discovery and development efforts primarily focus on high-value targets in immunology. We believe over 160 million patients in the United States, Europe, and Japan are diagnosed with prevalent immune-inflammatory diseases that our programs could address, with nearly half remaining untreated. Most treated patients receive therapies that address symptoms rather than underlying diseases. Approximately 3% of the diagnosed population with moderate to severe inflammatory diseases are currently treated with systemic advanced therapies, mostly injectable biologics. Biologics, while generally effective, are more expensive to manufacture, and patient access can be challenging due to prescription and reimbursement complexities compared to small molecule medicines.

Kymera Therapeutics, Inc. (NASDAQ:KYMR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 30 items for KYMR at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-29, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for KYMR spans 8-K, 10-Q, 4, SCHEDULE 13D/A.

Recent high-impact activity:

  • Kymera Q3 Loss Widens to $132M; KT-579 Phase 1 Achieves ≥90% IRF5 Degradation
  • Kymera Posts $1.32 Per-Share Q3 Loss as KT-621 Data Looms
  • Kymera Eyes Alzheimer's Data by Year-End, Phase 3 Start in 2027
  • Kymera Q2 2026: $65M Revenue, $1.5B Cash, Runway Into 2029
  • Kymera Q2 2026: KT-621 Phase 2b Enrollment Completed Early, Data by Year-End; $1.5B Cash Runway into 2029

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$39.21M
Net Income
-$311.35M
Diluted EPS
-$3.69
Op. Cash Flow
-$232.89M
Free Cash Flow
-$234.34M
Gross Profit
$0
Operating Income
-$349.4M
Cash & Equivalents
$357.01M
Debt / Equity
0.00×
Net Margin
-7.94×
Shares Outstanding
81.32M sh
Source: 10-K · filed 2026-02-26 · accession 0001193125-26-073395

Short Interest & Short Volume

10.49 days to cover

FINRA reported short interest of 8,400,784 shares in KYMR as of the October 30, 2026 settlement, a 8.4% decrease from the prior period — about 10.5 days to cover at its recent average daily volume. On November 20, 2026, 42.3% of KYMR volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)8,400,784 shares as of October 30, 2026
Change vs prior period▼ 8.4%
Days to cover10.49 at avg daily volume of 800,703
Daily short volume (FINRA facilities)42.3% of 468,304 shares on November 20, 2026
5-day average short volume55.3%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with K →
$124.06 +7.59% today
52-week range · as of 2026-10-29 $55.66 – $130.05
Market cap
$9.84B
Volume
1.3M (1.4× avg)
3-mo avg 931.1K
Live data · 2026-11-21 04:10 UTC · Market overnight

show_chartPrice Chart

Loading chart...

feed KYMR - Latest Insights

KYMR
Oct 29, 2026, 7:10 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $122.01
Real-time Price: $124.06 info
Change: +$2.05 (+2%) info
Market Cap: $9.844B info
KYMR
Oct 29, 2026, 7:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $122.01
Real-time Price: $124.06 info
Change: +$2.05 (+2%) info
Market Cap: $9.844B info
KYMR
Aug 06, 2026, 3:15 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $105.48
Real-time Price: $124.06 info
Change: +$18.58 (+18%) info
Market Cap: $9.844B info
KYMR
Aug 05, 2026, 7:15 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $104.52
Real-time Price: $124.06 info
Change: +$19.54 (+19%) info
Market Cap: $9.844B info
KYMR
Aug 05, 2026, 7:10 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $104.52
Real-time Price: $124.06 info
Change: +$19.54 (+19%) info
Market Cap: $9.844B info
KYMR
Jun 26, 2026, 6:48 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $108.12
Real-time Price: $124.06 info
Change: +$15.94 (+15%) info
Market Cap: $9.844B info
KYMR
Jun 26, 2026, 6:43 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $108.12
Real-time Price: $124.06 info
Change: +$15.94 (+15%) info
Market Cap: $9.844B info
KYMR
Jun 26, 2026, 6:13 PM EDT
Filing Type: 144
Importance Score:
9
Price at Filing: $108.12
Real-time Price: $124.06 info
Change: +$15.94 (+15%) info
Market Cap: $9.844B info
KYMR
Jun 26, 2026, 4:52 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $108.12
Real-time Price: $124.06 info
Change: +$15.94 (+15%) info
Market Cap: $9.844B info
KYMR
Jun 26, 2026, 4:51 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $108.12
Real-time Price: $124.06 info
Change: +$15.94 (+15%) info
Market Cap: $9.844B info
KYMR
Jun 25, 2026, 5:26 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $115.91
Real-time Price: $124.06 info
Change: +$8.15 (+7%) info
Market Cap: $9.844B info
KYMR
Jun 25, 2026, 5:25 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $115.91
Real-time Price: $124.06 info
Change: +$8.15 (+7%) info
Market Cap: $9.844B info
KYMR
Jun 25, 2026, 7:10 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $102.01
Real-time Price: $124.06 info
Change: +$22.05 (+22%) info
Market Cap: $9.844B info
KYMR
Jun 25, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $99.87
Real-time Price: $124.06 info
Change: +$24.19 (+24%) info
Market Cap: $9.844B info
KYMR
Jun 22, 2026, 5:28 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $99.45
Real-time Price: $124.06 info
Change: +$24.61 (+25%) info
Market Cap: $9.844B info
KYMR
Jun 22, 2026, 5:28 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $99.45
Real-time Price: $124.06 info
Change: +$24.61 (+25%) info
Market Cap: $9.844B info
KYMR
Jun 12, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $82.96
Real-time Price: $124.06 info
Change: +$41.10 (+50%) info
Market Cap: $9.844B info
KYMR
Jun 09, 2026, 7:02 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $73.95
Real-time Price: $124.06 info
Change: +$50.11 (+68%) info
Market Cap: $9.844B info
KYMR
Jun 08, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $73.95
Real-time Price: $124.06 info
Change: +$50.11 (+68%) info
Market Cap: $9.844B info
KYMR
May 05, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $83.59
Real-time Price: $124.06 info
Change: +$40.47 (+48%) info
Market Cap: $9.844B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets